Rallybio Corporation (RLYB)Healthcare | Biotechnology | New Haven, United States | NasdaqCM
8.22 USD
-0.11
(-1.321%) ⇩
(April 17, 2026, 4 p.m.
EDT)
After hours: 8.22 Short-term: ★★★☆☆ | Long-term: ☆☆☆☆☆ | Dividends: ☆☆☆☆☆ |
Hot Take | April 18, 2026, 11:40 p.m. EDT
RLYB is fundamentally insolvent with negative earnings, massive cash burn, and no dividends, rendering it a long-term trap. Its short-term upside is exclusively derived from high-risk speculation on a merger with Candid Therapeutics, making it an 'all-or-nothing' binary bet rather than an investment. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.373935 |
| AutoETS | 0.374498 |
| AutoARIMA | 0.374504 |
| MSTL | 0.376184 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 41% |
| H-stat | 69.26 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.084 |
| Excess Kurtosis | -1.61 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 0.304 |
| Revenue per Share | 0.152 |
| Market Cap | 43,481,128 |
| Forward P/E | -1.52 |
| Beta | -1.20 |
| Website | https://www.rallybio.com |
| Attribute | Value |
|---|---|
| 52 Week Change | 2.8773584 |
| Address1 | 234 Church Street |
| All Time High | 206.24 |
| All Time Low | 1.76 |
| Ask | 8.48 |
| Ask Size | 1 |
| Audit Risk | 8 |
| Average Analyst Rating | 3.0 - Hold |
| Average Daily Volume10 Day | 71,390 |
| Average Daily Volume3 Month | 142,453 |
| Average Volume | 142,453 |
| Average Volume10Days | 71,390 |
| Beta | -1.198 |
| Bid | 7.99 |
| Bid Size | 1 |
| Board Risk | 8 |
| Book Value | 10.97 |
| City | New Haven |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 8 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 8.22 |
| Current Ratio | 14.505 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 8.275 |
| Day Low | 8.11 |
| Debt To Equity | 0.304 |
| Display Name | Rallybio |
| Earnings Timestamp End | 1,754,569,800 |
| Earnings Timestamp Start | 1,754,569,800 |
| Ebitda | -31,272,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | 0.354 |
| Enterprise To Revenue | -12.912 |
| Enterprise Value | -11,078,872 |
| Eps Current Year | -5.52 |
| Eps Forward | -5.4 |
| Eps Trailing Twelve Months | -1.59 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 7.85536 |
| Fifty Day Average Change | 0.36464024 |
| Fifty Day Average Change Percent | 0.04641929 |
| Fifty Two Week Change Percent | 287.73584 |
| Fifty Two Week High | 11.49 |
| Fifty Two Week High Change | -3.2699995 |
| Fifty Two Week High Change Percent | -0.28459525 |
| Fifty Two Week Low | 1.96 |
| Fifty Two Week Low Change | 6.26 |
| Fifty Two Week Low Change Percent | 3.1938777 |
| Fifty Two Week Range | 1.96 - 11.49 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,627,565,400,000 |
| Float Shares | 3,163,067 |
| Forward Eps | -5.4 |
| Forward P E | -1.5222223 |
| Free Cashflow | -20,342,500 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 14 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,775,001,600 |
| Gross Margins | 0.0 |
| Gross Profits | -17,539,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.04157 |
| Held Percent Institutions | 0.57921004 |
| Implied Shares Outstanding | 5,289,675 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,021-07-29 |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,770,336,000 |
| Last Split Factor | 1:8 |
| Long Business Summary | Rallybio Corporation, a clinical-stage biotechnology company, engages in the development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is the RLYB116, an inhibitor of complement component 5 (C5) to treat several diseases of complement dysregulation which has completed phase 1 trial; and RLYB332, a preclinical antibody, for the treatment of severe anemia with ineffective erythropoiesis and iron overload. The company has a strategic alliance with AbCellera to discover, develop, and commercialize novel antibody-based therapeutics for rare diseases, as well as collaboration agreement with Johnson & Johnson to provide therapeutic solutions for pregnant individuals at risk of fetal and neonatal alloimmune thrombocytopenia. Rallybio Corporation was founded in 2018 and is headquartered in New Haven, Connecticut. |
| Long Name | Rallybio Corporation |
| Market | us_market |
| Market Cap | 43,481,128 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_1673028342 |
| Most Recent Quarter | 1,767,139,200 |
| Net Income To Common | -8,978,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 43,481,128 |
| Open | 8.26 |
| Operating Cashflow | -29,813,000 |
| Operating Margins | -28.882881 |
| Overall Risk | 7 |
| Payout Ratio | 0.0 |
| Phone | 203 859 3820 |
| Post Market Change | 0.0 |
| Post Market Change Percent | 0.0 |
| Post Market Price | 8.22 |
| Post Market Time | 1,776,456,605 |
| Previous Close | 8.33 |
| Price Eps Current Year | -1.4891305 |
| Price Hint | 2 |
| Price To Book | 0.74931633 |
| Price To Sales Trailing12 Months | 50.677307 |
| Profit Margins | 0.0 |
| Quick Ratio | 12.961 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | hold |
| Recommendation Mean | 3.0 |
| Region | US |
| Regular Market Change | -0.11 |
| Regular Market Change Percent | -1.32052 |
| Regular Market Day High | 8.275 |
| Regular Market Day Low | 8.11 |
| Regular Market Day Range | 8.11 - 8.275 |
| Regular Market Open | 8.26 |
| Regular Market Previous Close | 8.33 |
| Regular Market Price | 8.22 |
| Regular Market Time | 1,776,456,000 |
| Regular Market Volume | 32,584 |
| Return On Assets | -0.30072 |
| Return On Equity | -0.15012 |
| Revenue Growth | 4.842 |
| Revenue Per Share | 0.152 |
| Sand P52 Week Change | 0.38150132 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 5 |
| Shares Outstanding | 5,289,675 |
| Shares Percent Shares Out | 0.20959999 |
| Shares Short | 1,108,870 |
| Shares Short Previous Month Date | 1,772,150,400 |
| Shares Short Prior Month | 44,517 |
| Short Name | Rallybio Corporation |
| Short Percent Of Float | 0.2522 |
| Short Ratio | 3.67 |
| Source Interval | 15 |
| State | CT |
| Symbol | RLYB |
| Total Cash | 54,736,000 |
| Total Cash Per Share | 10.348 |
| Total Debt | 176,000 |
| Total Revenue | 858,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -1.59 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 5.55996 |
| Two Hundred Day Average Change | 2.6600404 |
| Two Hundred Day Average Change Percent | 0.47842798 |
| Type Disp | Equity |
| Volume | 32,584 |
| Website | https://www.rallybio.com |
| Zip | 6,510 |